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ABSTRACT

VL+UVA1-induced effects. This is concerning since the skin is
exposed to these wavelengths when outdoors.
While ultraviolet B (UVB) radiation causes direct DNA damage and erythema/sunburn by directly inducing cyclobutane
pyrimidine dimers, longer wavelengths such as UVA are poorly
absorbed by DNA and instead indirectly cause DNA damage by
generating reactive oxygen species (ROS) after absorption by ﬂavins, porphyrins and other chromophores (7–11). A wide variety
of stimuli and metabolic processes generate ROS, which strip
electrons from other molecules (oxidation) and generate more
ROS in a self-propagating chain reaction. This excess production
of oxidizing molecules is termed oxidative stress and leads to the
damage of lipids, proteins and nucleic acids. ROS and oxidative
stress are implicated in sunburn, carcinogenesis, inﬂammatory
diseases and aging. Oxidative stress also contributes to pigmentation (12). Alpha-melanocyte stimulating hormone (a-MSH), a
major stimulus of melanogenesis, reduces UV-induced hydrogen
peroxide levels in irradiated melanocytes, further supporting the
link between pigmentation and oxidative stress (13). DNA damage from solar radiation also stimulates melanogenesis, and
DNA repair is induced alongside pigmentation (11). Moreover,
short wavelength VL also upregulates melanogenesis through Gprotein-coupled membrane receptor opsin-3 (14). Since a possible mechanism of VL+UVA1-induced effects is oxidative stress,
targeting ROS, such as superoxide, hydroxyl radical and singlet
oxygen, may potentially mitigate the effects of VL+UVA1.
AOs are molecules that scavenge free radicals and terminate
the chain reactions that propagate ROS. Solar radiation is known
to deplete endogenous AO including glutathione, tocopherol and
ubiquinone (9). AO combinations using ingredients such as
feverfew extract, soy extract and tocopherol can halve visible
light-induced ROS induction (9). Other AO such as mannitol can
inhibit photo-oxidative damage from UVB (15). The combination
of diethylhexyl syringylidene malonate and vitamin E have been
shown to be effective in suppressing the formation of ROS
induced by UVA and UVB at 0.9% and 0.5%, respectively,
when added in sunscreen formulations and evaluated by twophoton ﬂuorescence microscopy (16). This data suggests a potential role for AO to mitigate pigmentation induced by VL+UVA1.

The role of topical antioxidants (AOs) on visible light plus
ultraviolet A1 (VL+UVA1)-induced skin changes were evaluated. Twenty subjects with skin phototypes (SPTs) I-VI had
placebo and concentrations of an AO blend applied to their
back (AO 0.5%, 1.0% and 2.0%). Treated and control sites
were irradiated with VL+UVA1. Colorimetric and diffuse
reﬂectance spectroscopy (DRS) assessments were performed
immediately, 24 h and 7 days after irradiation. Subjects with
SPT I-III had erythema that faded within 24 h, while SPT
IV-VI had persistent pigmentation. SPT I-III demonstrated
signiﬁcantly less erythema at the 2% AO site while SPT IVVI demonstrated signiﬁcantly less immediate pigmentation at
2% AO site and less pigmentation (approaching signiﬁcance,
P = 0.07) on day 7 compared with control. Immunohistochemistry from biopsies of 2% AO and placebo at 24 h did
not demonstrate a signiﬁcant change in COX-2 or MART-1
for any SPT. There was a decrease in cyclin D1 for SPT IVVI which was approaching signiﬁcance (P = 0.06) but not for
SPT I-III. The results indicate that topical AO inhibits erythema in SPT I-III and reduces pigmentation in SPT IV-VI
caused by VL+UVA1. AO may help prevent worsening of
pigmentary disorders and should be incorporated into photoprotection.

INTRODUCTION
Visible light (VL; 400–700 nm) has been demonstrated to cause
sustained pigmentation (1–5). Additionally, a small amount of
long-wavelength ultraviolet A1 radiation (UVA1, <4%) in combination with VL, (VL+UVA1, 370–700 nm) has a synergistic
effect on pigmentation and erythema (6). This has implications
for pigmentary disorders such as postinﬂammatory hyperpigmentation and melasma. The majority of currently available sunscreen products provide inadequate protection against
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However, there are limited studies regarding AO prevention of
either UV or VL-induced pigmentation. In this study, varying
concentrations of an AO product (Table 1) were tested for their
ability to mitigate VL+UVA1-induced pigmentation and erythema.

MATERIALS AND METHODS
Twenty subjects (12 males, 8 females), 10 with Fitzpatrick skin phototype
(SPT) I-III (0 SPT I, 9 SPT II, 1 SPT III) and 10 with SPT IV-VI (3 SPT
IV, 7 SPT V, 0 SPT VI), were enrolled. The study was approved by the
Institutional Review Board at Henry Ford Hospital and performed at
Henry Ford Hospital. Informed consent was obtained from all subjects.
All guidelines from the Declaration of Helsinki, good clinical practice
(GCP), and international conference on harmonization (ICH) were
followed. Subjects had all avoided excessive sun exposure for one month
prior to participating in the study. Subjects who had photo-aggravated
conditions or photodermatoses, a history of skin cancer or a history
allergy to sunscreens or topical products were excluded from the study.
Those who were on photo-sensitizing medications, pregnant or
breastfeeding were also excluded. All subjects stated a willingness to
avoid intentional sun exposure for the duration of the study. Subjects did
not use any topical or systemic products which could interfere with the
assessments during the course of the study.
A modiﬁed solar simulator was utilized: Solar Light LS1000 with
xenon arc lamp and customized ﬁlters (Solar Light Company Inc, Glenside, PA), ﬁltered spectral output consisting of 2.0% UVA1 (340–
400 nm), 97.3% VL (400–700 nm) and 0.7% Infrared (700–1600 nm)
(Fig. 1) (17). Table 1 shows the AO blend topical formulations containing variable concentrations of a singlet oxygen quencher (diethylhexyl
syringylidene malonate) and ﬁxed concentrations of vitamins used in this
study.
On day 0, small areas of the subjects’ backs were occluded for 1 h
with different concentrations of the AO blend: 0.5%, 1.0%, 2.0%, a
duplicate 2.0% site for biopsy and placebo. These sites, as well as
untreated sites, were then irradiated with 480 J cm 2 of VL+UVA1 in
the SPT I-III group and 320 J cm 2 in the SPT IV-VI group at an irradiance of approximately 86 mW cm 2. These doses have previously been
established to be the minimum necessary to induce sustained erythema
and pigmentation in their respective SPTs (6).
Investigator Global Assessment scores (IGA), colorimetric and spectroscopic (DRS) assessments were performed immediately, at 24 h and
7 days after irradiation (6). IGA scoring (Table 2) was performed by a
blinded single grader. For the colorimetry measurements, Da parameter,
herein referred to as relative erythema, was used to assess erythema and
the change in individual typology angle (DITA) was used to assess pigmentation. For DRS, the overall darkness of the site was assessed as relative pigment. This was calculated via the area under the curve (AUC) of
the differential apparent absorbance spectra between 400 and 700 nm
(18).
In addition, 4-mm punch biopsies were obtained 24 h after irradiation
from sites treated with placebo and 2% AO. Inﬂammation, cell

Table 1. AO blend composition.
AO
Blend
Placebo
Ingredients
Diethylhexyl
Syringylidene Malonate,
Oxynex STâ
Vitamin E, USP
C12 15 Alkyl Benzoate,
Tegosoft TN2â
Ascorbyl Palmitate NF
Alcohol SD 40-B
Propylene Glycol, USP
Total

–

AO
Blend
0.5%

AO
Blend
1%

AO
Blend
2%

0.50%

1.00%

2.00%

–
50.00%

0.25%
50.00%

0.25%
50.00%

0.25%
50.00%

–
40.00%
10.00%
100.00%

0.01%
39.24%
10.00%
100.00%

0.01%
38.74%
10.00%
100.00%

0.01%
37.74%
10.00%
100.00%

Figure 1. Spectral output of the solar simulator.

Table 2. Investigator’s Global Assessment (IGA) scores.
IGA
0
1
2
3
4
5

Description for
hyperpigmentation
Clear of hyperpigmentation
Almost clear of
hyperpigmentation
Mild, but noticeable
hyperpigmentation
Moderate hyperpigmentation
(medium brown in quality)
Severe hyperpigmentation (dark
brown in quality)
Very severe hyperpigmentation
(very dark brown, almost black
in quality)

Description for erythema
Clear of erythema
Almost clear of erythema
Mild, but noticeable erythema
Moderate erythema (pink in
quality), no sharp borders
Severe erythema (dark pink in
quality), sharp borders
Very severe erythema (very
dark pink, almost red in
quality)

proliferation and melanocyte count of formalin-ﬁxed, parafﬁn-embedded
tissue sections were compared by counting cells staining positively for
cyclooxygenase-2 (COX-2), cyclin D1 and MART-1, respectively. Slides
were examined using an Olympus BX51 microscope at 40x magniﬁcation. MART-1-staining cells were counted across ﬁve 40x ﬁelds. COX-2
and cyclin D1-staining cells were counted in three 409 ﬁelds. Nuclear
cyclin D1 staining and red cytoplasmic COX-2 staining were considered
positive.
Data analysis was done separately for subjects with SPT I-III and
those with SPT IV-VI. Within each SPT group, the primary analysis was
to compare the erythema and hyperpigmentation scores as well as colorimetry and DRS results between the untreated site and each of the three
treated sites using paired t-tests with the Hochberg multiple comparison
methodology. For the three comparison results, the smallest P-value
would be signiﬁcant if it was less than 0.0167, the middle P-value would
be signiﬁcant if it was less than 0.0333 and the largest P-value would be
signiﬁcant if it was <0.05.

RESULTS
VL+UVA1-induced erythema, particularly in SPT I-III subjects,
was most intense immediately after irradiation and faded within
24 h (Fig. 2a). This group did not develop as much pigmentation
as the SPT IV-VI group at any time point. Subjects with SPT
IV-VI had intense pigmentary responses to VL+UVA1 with the
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most intense response observed immediately after irradiation (immediate pigment darkening) (Fig. 2b).
For subjects with SPT I-III, Fig. 3a–c represents average IGA
scores for erythema, colorimetry-measured Da and DRSmeasured AUC, respectively, performed immediately after
VL+UVA1 irradiation. Colorimetry Da and DRS-measured AUC
demonstrated that sites treated with 2% AO had signiﬁcantly less
erythema compared with untreated control (Fig. 3b,c). The 2%
AO sites also had less erythema by IGA scores, however statistical signiﬁcance was not reached (Fig. 3a). Figure 3d–f represents
average IGA scores for pigmentation, colorimetry-measured
DITA and DRS-measured AUC performed 7 days after
VL+UVA1 irradiation in SPT I-III subjects. As seen in Fig. 3d,
very mild clinical pigmentation was observed. That said, objective instrumental assessment did capture pigment formation. The
DITA demonstrated that sites treated with 1% and 2% AO had
less pigmentation relative to the untreated control, although statistical signiﬁcance was not reached, but was approaching
(P = 0.09 for 1% AO blend and P = 0.08 for 2% AO blend,
Fig. 3e). DRS measured AUC, which accounts for overall darkness, demonstrated that 2% AO sites were statistically signiﬁcantly lighter compared with untreated control (Fig. 3f).
For subjects with SPT IV-VI, Fig. 4a–c represents IPD evaluations as assessed by average IGA scores for pigmentation,
colorimetry-measured DITA and DRS-measured AUC, respectively, performed immediately after irradiation with VL+UVA1.
Sites treated with 2% AO had less IPD relative to untreated control (Fig. 4a–c). A statistically signiﬁcant difference was
observed for colorimetry-measured DITA values (Fig. 4b) but
not for clinical IGA scores for pigmentation and DRS measured
AUC. Figure 4d–f represents delayed tanning (DT) evaluations
as assessed by average IGA scores for pigmentation,
colorimetry-measured DITA and DRS-measured AUC performed
7 days after VL+UVA1 irradiation in SPT IV-VI subjects. The
colorimetry-measured DITA for the sites treated with 2% AO
blend was approaching signiﬁcance (P = 0.07) when compared
with the untreated control. There was no statistically signiﬁcant
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difference in pigmentation for IGA scores and DRS-measured
AUC for pigmentation between untreated control and AO treated
sites.
There were no signiﬁcant differences observed on immunohistochemical analysis of placebo and 2% AO blend treated biopsy
sites 24 h after irradiation in all SPT for COX-2 and MART-1
staining (Fig. 5). Of note, the immunochemical analysis of placebo and 2% of AO blend-treatment for Cyclin D1 was
approaching signiﬁcance (P = 0.06) for SPT IV-VI. This trend
in cyclin D1 was not observed for SPT I-III (Fig. 5).

DISCUSSION
The VL+UVA1 doses used in this study, 480 and 320 J cm 2,
correspond to approximately 2.5 and 1.5 h of outdoor sun exposure, respectively (17). The DRS and colorimetry data demonstrated that the 2.0% AO blend concentration provided protection
against VL+UVA1-induced immediate erythema and delayed
pigmentation in light-skinned individuals (SPT I-III). The colorimetry DITA data also indicated that 2.0% AO provided some
protection against VL+UVA1-induced immediate and delayed
pigmentation in the melanocompetent group (SPT IV-VI).
Melanocompetent refers to having melanin to protect against sun
damage. Conditions including postinﬂammatory hyperpigmentation and melasma are common in light skinned and melanocompetent groups and can be worsened by sun exposure. In addition,
other dermatologic conditions can be triggered or exacerbated by
exposure to VL and/or UVA1 including cutaneous porphyrias,
solar urticaria and chronic actinic dermatitis (19). Thus, photoprotection is an important part of management in these patients.
The fact that VL+UVA1 causes pigmentation and may cause
oxidative DNA damage reveals limitations in current photoprotection strategies. None of the currently available organic UV ﬁlters listed in FDA monograph protects against VL (20). While
pigmentary grade inorganic ﬁlters (titanium dioxide and zinc
oxide) provide protection against VL, they are not widely used
in sunscreen products as they leave noticeable white residue on

Figure 2. Photographs of sites immediately, 24 h and 7 days after VL+UVA1 irradiation for subjects with (a) SPT I-III and (b) SPT IV-VI.
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Figure 3. Erythema and pigmentation in SPT I-III subjects. Average IGA scores for erythema (a), colorimetry-measured relative erythema (b) and
DRS-measured AUC (c) immediately after VL+UVA1 irradiation. Average IGA scores for pigmentation (d), colorimetry-measured DITA (e) and DRSmeasured AUC (f) 7 days after VL+UVA1 irradiation.

Figure 4. Immediate pigmentation and delayed tanning in SPT IV-VI subjects. Average IGA scores for pigmentation (a), colorimetry-measured DITA
(b) and DRS-measured AUC (c) immediately after VL+UVA1 irradiation. Average IGA scores for pigmentation (d), colorimetry-measured DITA (e) and
DRS-measured AUC (f) 7 days after VL+UVA1 irradiation.
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Figure 5. Immunohistochemical staining results. No signiﬁcant differences observed in (a) COX-2, (b) cyclin D1 and (c) MART-1 between placebo
and 2% AO blend 24 h after irradiation for those with SPT I-III. No signiﬁcant differences observed in (d) COX-2 and (f) MART-1, while (e) cyclin
D1 was approaching signiﬁcance (P = 0.06) between placebo and 2% AO blend 24 h after irradiation for those with SPT IV-VI.

the skin. Inorganic ﬁlters are most commonly incorporated into
the ﬁnal products as nanosized particles to improve the cosmesis;
however, because of their small diameters, they do not reﬂect
visible light (18,19). Currently, the only available sunscreens that
have the potential to down-regulate VL-induced skin changes are
tinted sunscreens. These sunscreens contain iron oxides (listed as
inactive ingredients), or pigmentary titanium dioxide, all reﬂect
VL (19).
Recent studies have explored other topical and oral AO
against UV as well as VL-induced photodamage. Licochalcone
A (LicA), extracted from the roots of Glycyrrhiza inﬂata, has
been identiﬁed as very potent AO which inhibits UV-induced
ROS generation, activates NRF2 in primary human ﬁbroblasts,
and has a protective effect on cutaneous carotenoids in vivo (20).
Carotenoids, which are available orally and topically, help
prevent free radical formation, inﬂammation and pigment deposition through tyrosinase inhibition (21). A randomized, doubleblind, placebo controlled clinical trial in 46 subjects using an
oral carotenoid vs placebo for 12 weeks demonstrated statistically signiﬁcantly less erythema post UV irradiation in the oral
carotenoid group compared to placebo (21).
Polyphenols are another class of AO which scavenge free radicals and inhibit tyrosinase-catalyzed oxidation (22, 23). Green
and white tea, and pomegranate extract all contain polyphenols.
Oral and topical administration of green tea has been shown in
mouse models to protect against UV-induced carcinogenesis
(24). Several studies of topical green tea have also shown protection against UV-induced damage in humans by way of prevention of UV-induced erythema, generation of ROS, damage to
Langerhans cells and formation of cyclobutane pyrimidine
dimers (25–28). Administration of oral green tea has also shown

reduction in UV-induced erythema in humans (29). Similarly, a
study in which 13 subjects received oral pomegranate extract
containing polyphenols compared with placebo found that there
was a statistically signiﬁcant reduction in pigmentation in the
polyphenol treatment group after UV irradiation when compared
with placebo (30).
The impact of oral Polypodium leucotomos extract (PLE) was
recently evaluated against VL effects. PLE contains polyphenols
and has been shown to reduce oxidative stress, inﬂammation and
DNA damage via prevention of membrane-lipid peroxidation,
reducing glutathione oxidation and quenching free radicals following UVA and UVB irradiation in mice, ex vivo and in vivo
(31,32). Twenty-two subjects underwent VL irradiation prior to
PLE administration and were followed for 7 days to assess baseline response (33). VL irradiation was performed on the contralateral side of the subject’s back after 28 days of PLE
supplementation. Pre- and post-PLE responses demonstrated no
difference in clinical assessments; however, instrumental assessments suggested a statistically signiﬁcant decrease in pigment
formation (33).
While the studies discussed above evaluated oral AO supplements and explored the effects of UV irradiation alone or VL
alone, this study investigated the impact of topical AO on the
synergistic effects of VL plus long wavelength UVA1. As the
data in this study shows, the concentration of AO must be sufﬁcient to have a signiﬁcant effect. Limitations of this study
include a relatively small sample size, investigation of only the
AO in this product, limited information on how the product
affects biologic pathways and limited information regarding optimal biopsy timeline acquisition. Future studies should test full
formulation products to assess for efﬁcacy and protection.
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Results of this study cannot be generalized to all AO blends on
the market. Different AO blends could have different properties
and will need to be evaluated prior to claiming any protection.
Future areas of research should also include comparing the
in vivo effectiveness of fully formulated product with investigated AO as an ingredient, and efﬁcacy evaluation of different
AO/sunscreen combinations to real world situations.

REFERENCES
1. Randhawa, M., I. Seo, F. Liebel, M. D. Southall, N. Kollias and E.
Ruvolo (2015) Visible light induces melanogenesis in human skin
through a photoadaptive response. PLoS One 10(6), e0130949.
2. Ramasubramaniam, R., A. Roy, B. Sharma and S. Nagalakshmi
(2011) Are there mechanistic differences between ultraviolet and visible radiation induced skin pigmentation? Photochem. Photobiol. Sci.
10(12), 1887–1893.
3. Duteil, L., N. Cardot-Leccia, C. Queille-Roussel, Y. Maubert, Y.
Harmelin, F. Boukari, D. Ambrosetti, J.-P. Lacour and T. Passeron
(2014) Differences in visible light-induced pigmentation according to
wavelengths: a clinical and histological study in comparison with
UVB exposure. Pigment Cell Melanoma Res. 27(5), 822–826.
4. Porges, S., K. Kaidbey and G. Grove (1988) Quantiﬁcation of visible
light-induced melanogenesis in human skin. Photo-dermatology 5(5),
197–200.
5. Mahmoud, B. H., E. Ruvolo, C. L. Hexsel, Y. Liu, M. R. Owen, N.
Kollias, H. W. Lim and I. H. Hamzavi (2010) Impact of longwavelength UVA and visible light on melanocompetent skin. J.
Investigat. Dermatol. 130(8), 2092–2097.
6. Kohli, I., S. Chaowattanapanit, T. F. Mohammad, C. L. Nicholson,
S. Fatima, G. Jacobsen, N. Kollias, H. W. Lim and I. H. Hamzavi
et al. (2018) Synergistic effects of long-wavelength ultraviolet al and
visible light on pigmentation and erythema. Br. J. Dermatol. 178(5),
1173–1180.
7. Kielbassa, C., L. Roza and B. Epe (1997) Wavelength dependence
of oxidative DNA damage induced by UV and visible light. Carcinogenesis 18(4), 811–816.
8. Cadet, J., T. Douki, J. L. Ravanat and P. Di Mascio (2009) Sensitized formation of oxidatively generated damage to cellular DNA by
UVA radiation. Photochem. Photobiol. Sci. 8(7), 903–911.
9. Liebel, F., S. Kaur, E. Ruvolo, N. Kollias and M. D. Southall (2012)
Irradiation of skin with visible light induces reactive oxygen species
and matrix-degrading enzymes. J. Invest. Dermatol. 132(7), 1901–
1907.
10. Nishigori, C., Y. Hattori and S. Toyokuni (2004) Role of reactive
oxygen species in skin carcinogenesis. Antioxid. Redox Signal. 6(3),
561–570.
11. Premi, S., S. Wallisch, C. M. Mano, A. B. Weiner, A. Bacchiocchi,
K. Wakamatsu, E. J. H. Bechara, R. Halaban, T. Douki and D. E.
Brash (2015) Chemiexcitation of melanin derivatives induces DNA
photoproducts long after UV exposure. Science 347(6224), 842–847.
12. Agar, N. and A. R. Young (2005) Melanogenesis: a photoprotective
response to DNA damage? Mutat Res 571(1), 121–132.
13. Song, X., N. Mosby, J. Yang, A. Xu, Z. Abdel-Malek and A. L.
Kadekaro (2009) a-MSH activates immediate defense responses to
UV-induced oxidative stress in human melanocytes. Pigment Cell
Melanoma Res 22(6), 809–818.
14. Regazzetti, C., L. Sormani, D. Debayle, F. Bernerd, M. K. Tulic, G.
M. De Donatis, B. Chignon-Sicard, S. Rocchi and T. Passeron
(2018) Melanocytes sense blue light and regulate pigmentation
through opsin-3. J. Investigat. Dermatol. 138(1), 171–178.
15. Pelle, E., X. Huang, T. Mammone, K. Marenus, D. Maes and K.
Frenkel (2003) Ultraviolet-B-induced oxidative DNA base damage in
primary normal human epidermal keratinocytes and inhibition by a
hydroxyl radical scavenger. J. Invest. Dermatol. 121(1), 177–183.
16. Hamson, K., C. J. Bardeen, D. Beasley and T. A. Meyer (2011)
Antioxidants in Sunscreens for Improved ROS Protection. Cosmetic
Toiletries 126(10), 710–718.

17. Kohli, I., R. Zubair, A. B. Lyons, A. F. Nahhas, T. L. Braunberger,
M. Mokhtari, E. Ruvolo, H. W. Lim and I. H. Hamzavi (2019)
Impact of long-wavelength ultraviolet al and visible light on lightskinned individuals. Photochem. Photobiol. 95(6), 1285–1287.
18. Kohli, I., A. F. Nahhas, T. L. Braunberger, S. Chaowattanapanit, T.
F. Mohammad, C. L. Nicholson, N. Kollias, H. W. Lim and I. H.
Hamzavi (2019) Spectral characteristics of visible light-induced pigmentation, and visible light protection factor. Photodermatol. Photoimmunol. Photomed. 35(6), 393–399.
19. Lyons, A. B., C. Trullas, I. Kohli, I. H. Hamzavi and H. W. Lim
(2020) Photoprotection beyond ultraviolet radiation: A review of
tinted sunscreens. J. Am. Acad. Dermatol. 84(5), 1393–1397.
20. Geisler, A. N., E. Austin, J. Nguyen, I. Hamzavi, J. Jagdeo and H.
W. Lim (2021) Visible light. Part II. Photoprotection against visible
and ultraviolet light. J. Am. Acad. Dermatol. 84(5), 1233–1244.
21. Juturu, V., J. P. Bowman and J. Deshpande (2016) Overall skin tone
and skin-lightening-improving effects with oral supplementation of
lutein and zeaxanthin isomers: a double-blind, placebo-controlled
clinical trial. Clin. Cosmet. Investig. Dermatol. 9, 325–332.
22. An, S. M., H. J. Kim, J. E. Kim and Y. C. Boo (2008) Flavonoids,
taxifolin and luteolin attenuate cellular melanogenesis despite
increasing tyrosinase protein levels. Phytotherapy Res. 22(9), 1200–
1207.
23. Chen, Y. T., R. L. Zheng, Z. J. Jia and Y. Ju (1990) Flavonoids as
superoxide scavengers and antioxidants. Free Radic. Biol. Med. 9(1),
19–21.
24. Sharma, P., M. K. Montes de Oca, A. R. Alkeswani, S. F. McClees,
T. Das, C. A. Elmets and F. Afaq (2018) Tea polyphenols for the
prevention of UVB-induced skin cancer. Photodermatol. Photoimmunol. Photomed. 34(1), 50–59.
25. Camouse, M. M., D. S. Domingo, F. R. Swain, E. P. Conrad, M. S.
Matsui, D. Maes, L. Declercq, K. D. Cooper, S. R. Stevens and E.
D. Baron (2009) Topical application of green and white tea extracts
provides protection from solar-simulated ultraviolet light in human
skin. Exp. Dermatol. 18(6), 522–526.
26. Katiyar, S. K., M. S. Matsui, C. A. Elmets and H. Mukhtar (1999)
Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea
reduces UVB-induced inﬂammatory responses and inﬁltration of
leukocytes in human skin. Photochem. Photobiol. 69(2), 148–153.
27. Katiyar, S. K., A. Perez and H. Mukhtar (2000) Green tea polyphenol treatment to human skin prevents formation of ultraviolet light
B-induced pyrimidine dimers in DNA. Clin. Cancer Res. 6(10),
3864–3869.
28. Elmets, C. A., D. Singh, K. Tubesing, M. Matsui, S. Katiyar and H.
Mukhtar (2001) Cutaneous photoprotection from ultraviolet injury by
green tea polyphenols. J. Am. Acad. Dermatol. 44(3), 425–432.
29. Rhodes, L. E., G. Darby, K. A. Massey, K. A. Clarke, T. P. Dew,
M. D. Farrar, S. Bennett, R. E. B. Watson, G. Williamson and A.
Nicolaou (2013) Oral green tea catechin metabolites are incorporated
into human skin and protect against UV radiation-induced cutaneous
inﬂammation in association with reduced production of proinﬂammatory eicosanoid 12-hydroxyeicosatetraenoic acid. Brit J.
Nutr. 110(5), 891–900.
30. Kasai, K., M. Yoshimura, T. Koga, M. Arii and S. Kawasaki (2006)
Effects of oral administration of ellagic acid-rich pomegranate extract
on ultraviolet-induced pigmentation in the human skin. J. Nutr. Sci.
Vitaminol. 52(5), 383–388.
31. Mulero, M., E. Rodriguez-Yanes, M. R. Nogues, M. Giralt, M.
Romeu, S. Gonzalez (2008) Polypodium leucotomos extract inhibits
glutathione oxidation and prevents Langerhans cell depletion induced
by UVB/UVA radiation in a hairless rat model. Exp. Dermatol. 17
(8), 653–658.
32. Nahhas, A. F., Z. A. Abdel-Malek, I. Kohli, T. L. Braunberger, H.
W. Lim and I. H. Hamzavi (2019) The potential role of antioxidants
in mitigating skin hyperpigmentation resulting from ultraviolet and
visible light-induced oxidative stress. Photodermatol. Photoimmunol.
Photomed. 35(6), 420–428.
33. Mohammad, T. F., I. Kohli, C. L. Nicholson, G. Treyger, S.
Chaowattanapanit and A. F. Nahhas (2019) Oral polypodium leucotomos extract and its impact on visible light-induced pigmentation in
human subjects. J. Drugs Dermatol. 18(12), 1198–1203.

